Do GLP-1 medications (such as Ozempic) help you age more healthily?

GLP-1 agents such as semaglutide are currently among the better-supported medication options for people with obesity combined with diabetes, heart disease, or kidney disease. The numbers are concrete: roughly 20% lower risk of serious cardiovascular events, 24% slower kidney decline, and in the broad meta-analysis 12% lower mortality. These results were measured in large, carefully designed studies, and the causal relationship is on solid ground. However, those results apply specifically to people with that combination of conditions; someone who has only excess weight but is otherwise healthy falls outside the studied populations, and it is not certain that the benefit is equally large.

If you frame the question differently, namely whether these agents slow ageing or extend lifespan beyond those disease-related gains, the honest answer is: we do not know. There is one small study in 84 people with HIV that observed a change on an epigenetic clock, an indirect biological measure of ageing. That is interesting, but far too limited to act on. That study was also not conducted in a general population.

One point worth mentioning: of the weight lost on these agents, on average roughly one quarter consists of muscle mass. For people who are already focused on weight loss or want to age healthily, that is a factor to take into account, for example by consciously incorporating protein intake and strength training if you were ever to start them. Practically speaking, these are prescription medications that a doctor prescribes and supervises; they are not available or approved as a general anti-ageing agent.

This is a rapidly developing field, so if you would like me to keep you informed as better ageing data become available, I can do that.